Keywords: phase, ii, results, zeneca, tomudex, new, anticancer

Phase II Results With Zeneca's Tomudex

Article | 28 November 1994

Zeneca's new anticancer agent Tomudex (ZD1694), a quinazoline-based thymidylate synthase inhibitor, has significant activity in advanced colorectal cancer with tolerable ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Carac

Fluorouracil

Efudex

Go to drug listing